文献速递临床试验与 GCP

冠状动脉旁路移植术中移植自体心房附件微移植物的AAMS2随机双盲安慰剂对照试验设计

Autologous atrial appendage micrografts transplanted during coronary artery bypass surgery: design of the AAMS2 randomized, double-blinded, and placebo-controlled trial.
PubMed 文献 · Trials · 2026-01-02

AAMS2是一项随机、双盲、安慰剂对照试验,纳入择期行冠状动脉旁路移植术(CABG)且术前心脏磁共振(CMRI)延迟钆增强显示缺血性心肌瘢痕的缺血性心脏病(IHD)患者,按1:1随机接受含或不含自体右心房附件微移植物(AAMs)的胶原基质补片(Hemopatch®)心外膜移植至瘢痕边缘。主要终点为术前与术后6个月CMRI评估的左心室瘢痕质量,共同主要终点为血N末端B型利钠肽原(NT-proBNP)水平变化。

要点

  • AAMS2试验在CABG术中比较含AAMs的补片与不含AAMs的补片移植至缺血性心肌瘢痕边缘的疗效。
  • 主要终点为术前与术后6个月CMRI评估的左心室瘢痕质量,共同主要终点为血NT-proBNP水平变化。
  • 次要终点包括补片部位瘢痕质量变化、治疗安全性与可行性及超声心动图评估的心肌结构与功能。

核心结论

  • AAMS2试验将提供首个关于心外膜AAMs移植治疗缺血性心肌瘢痕的随机、盲法、安慰剂对照疗效评估数据。
  • 该数据将为合理设计更大规模的AAMs治疗疗效试验铺平道路。

研究设计与样本

  • AAMS2是一项随机、双盲、安慰剂对照试验,纳入择期行CABG且术前CMRI延迟钆增强显示缺血性心肌瘢痕的IHD患者。
  • 患者按1:1随机接受含或不含AAMs的胶原基质补片(Hemopatch®)心外膜移植至瘢痕边缘。
  • 主要终点为术前与术后6个月随访时CMRI评估的左心室瘢痕质量。
  • 共同主要终点为血NT-proBNP水平在该时间段的变化。
  • 次要终点包括补片部位瘢痕质量变化、治疗安全性与可行性及超声心动图评估的心肌结构与功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The AAMS open-label clinical study demonstrated the safety and feasibility of epicardial transplantation of autologous right atrial appendage micrografts (AAMs) during coronary artery bypass grafting (CABG) surgery. The study also provided the first indications of therapeutic efficacy of the AAMs, as delivered within an extracellular matrix patch, to reduce ischemic scar and increase viable ventricular wall thickness. To further evaluate the initial beneficial effects observed in the AAMS study, we designed the randomized, double-blinded, and placebo-controlled AAMS2 trial. Focusing on patients with ischemic heart disease (IHD) and myocardial scar, the AAMS2 trial aims to generate state-of-the-art structural and functional imaging data of the myocardium treated with an AAMs-patch during CABG. METHODS: The AAMS2 trial recruits IHD patients who are set to undergo non-urgent CABG and present with an ischemic myocardial scar in preoperative cardiac magnetic resonance imaging (CMRI) with late gadolinium enhancement. Patients are randomized (1:1) to receive a collagen-based matrix patch (Hemopatch®), with or without AAMs, epicardially onto the scar border. The primary endpoint, assessed by CMRI preoperatively and at 6 months post-operative follow-up, focuses on the left ventricle scar mass. The secondary endpoints center on the change in scar mass by the AAMs-patch site and evaluation of therapy safety and feasibility as well as its effects on myocardial structure and function by echocardiography. Change in blood N-terminal-pro-BNP levels in the timeframe is the co-primary endpoint. DISCUSSION: Data from the AAMS2 trial provides the first randomized, blinded, and placebo-controlled evaluation of efficacy on epicardial AAMs transplantation for ischemic myocardial scar. This data will pave the road towards rational design of larger AAMs therapeutic efficacy-addressing trial(s). TRIAL REGISTRATION: ClinicalTrials.gov, NCT05632432, registered 30 November 2022, https://clinicaltrials.gov/study/NCT05632432 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sikorski V, Nummi A, Kuuva A, et al. Autologous atrial appendage micrografts transplanted during coronary artery bypass surgery: design of the AAMS2 randomized, double-blinded, and placebo-controlled trial. Trials. 2026. PMID: 41485016. doi:10.1186/s13063-025-09379-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。